Recent Investment Analysts’ Ratings Changes for Icon Plc (ICLR)

Icon Plc (NASDAQ: ICLR) has recently received a number of price target changes and ratings updates:

  • 10/11/2017 – Icon Plc was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $128.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 10/9/2017 – Icon Plc had its price target raised by analysts at Jefferies Group LLC from $122.00 to $132.00. They now have a “buy” rating on the stock.
  • 10/4/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 10/2/2017 – Icon Plc was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 9/22/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/18/2017 – Icon Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $125.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/15/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/12/2017 – Icon Plc had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $122.00 price target on the stock.
  • 9/11/2017 – Icon Plc is now covered by analysts at Bank of America Corporation. They set a “buy” rating and a $128.00 price target on the stock.
  • 9/9/2017 – Icon Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $131.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/7/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/1/2017 – Icon Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $126.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/1/2017 – Icon Plc was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 8/29/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 8/24/2017 – Icon Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $120.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 8/22/2017 – Icon Plc was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/18/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “

Icon Plc (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.01. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The company had revenue of $431.00 million during the quarter, compared to analysts’ expectations of $430.68 million. During the same quarter in the prior year, the company earned $1.14 EPS. The firm’s revenue was up 5.0% on a year-over-year basis.

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply